Only randomized controlled trials, either pragmatic or explanatory, can provide more conclusive answers for this important clinical question 1).
In 2018, a systematic review and meta-analysis showed that resuming anticoagulant therapy after interruption for anticoagulation-associated intracranial hemorrhage reduced the risks of thromboembolic events, without significantly increasing the risks of ICH recurrence and long-term mortality 2).
see Anticoagulation Resumption after chronic subdural hematoma.
see Anticoagulation Resumption after intracerebral hemorrhage.
see Anticoagulation Resumption after traumatic brain injury.